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Abstract: 
Objectives: 
In synovial tissues of rheumatoid arthritis (RA) patients strong expression of laminins and 
integrins co-localizes with elevated expression of inflammatory cytokines. Synovial fibroblasts 
(SF) contribute to the pathogenesis of RA through elevated expression of cytokines and 
chemoattractant factors, one of which is IL-16. We therefore investigated regulatory pathways of 
IL-16 in SF from RA and osteoarthritis (OA) patients.  
Methods: 
SF were seeded in laminin-coated flasks and activated by the addition of cytokines. 
Expression of IL-16 was investigated by quantitative RT-PCR, immunoblotting, and ELISA; its 
biological activity was determined by a cell migration assay. Cell - matrix interactions were 
investigated by cell binding and attachment assays. Relevant intracellular signaling pathways 
were studied by immunoblotting and with pharmacological blocking reagents.  
Results: 
The stimulation of SF with TGF-β1 and growth on laminin-111 (LM-111) significantly 
increased the expression of IL-16. In RA-SF, binding to LM-111 induced significantly more IL-
16 mRNA than in OA-SF (p<0.05). The IL-16 cytokine was detected in supernatants of TGF-β1-
activated and in LM-111 plus TGF-β1-activated RA-SF (38 to 62 pg/ml), but not in supernatants 
of OA-SF. This IL-16 regulation involved p38MAPK, ERK1/2 and SMAD2 signaling, but not 
NFκB. 
Conclusions: 
Binding of RA-SF to LM-111 in the presence of TGF-β1 triggers a significant IL-16 
response and thus may contribute to the infiltration of CD4+ lymphocytes into synovial tissues. 
This mode of IL-16 induction represents a novel pathway leading to IL-16 production in RA-SF 
but not in OA-SF, and it operates independently of NFκB signaling. 
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 In RA elevated expression of cytokines and chemoattractant factors evokes a massive 
infiltration of mononuclear cells in the synovial tissue [1]. One of these factors, IL-16, is 
involved in the accumulation of Th-lymphocytes in the RA synovium [2-6]. IL-16 binds to CD4 
on Th-lymphocytes, macrophages, dendritic cells and eosinophils [7-12]. Elevated expression of 
IL-16 has been reported in different autoimmune disorders and it has been detected in the 
bronchial mucosa of asthmatic airways, in inflammatory lesions of multiple sclerosis patients, 
during neuronal degeneration, and in allergic patients [13-17]. IL-16 preferentially induces Th1-
lymphocyte migration [18]. Anti-IL-16 therapy reduced the infiltration of Th-lymphocytes and 
improved the pathology of experimental autoimmune encephalomyelitis [16]. Depending on the 
co-stimulatory signals or target cells, IL-16 may act as a chemoattractant factor contributing to 
inflammation [12, 13], function as an anti-inflammatory cytokine [19], or modulate allergen-
induced cytokine expression [20]. 
In RA synovial fluid, high titers of IL-16 correlate with recent onset of disease and disease 
progression [2]. Synovial CD68- lining cells display particularly strong staining for IL-16 mRNA 
[2, 4], suggesting that SF are an important source of IL-16. Elevated expression of laminins and 
their corresponding integrin receptors was found in the synovial lining of RA patients [21] and on 
RA-SF in vitro [22], prompting us to pose the question if binding of SF to laminins influences IL-
16 expression.  
Regulation of IL-16 responses has been studied in cells of different lineages [5, 23-31]. But 
to date there are no reports of investigations into a possible regulation of the expression of IL-16 
by extracellular matrix proteins. Elevated expression of MMP-3 has been observed in SF 
activated by TGF-β1 upon binding to LM-111 [32]. Here we report that binding to LM-111 in the 
presence of TGF-β1 induces a significant IL-16 response in RA-SF but not in OA-SF or orbital 
fibroblasts. 
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MATERIALS AND METHODS 
Cell culture  
Synovial tissue samples were obtained from 17 RA and 24 OA patients diagnosed 
according to the revised ACR criteria [33]. Orbital tissue was obtained from surgical waste [5]. 
The fibroblasts were prepared and expanded in DMEM medium enriched with ITS, FCS and 
antibiotics (= complete medium) as described elsewhere [5, 34]. This study was approved by the 
local ethics committee. 
 
For mRNA induction studies, SF were incubated in complete medium enriched with rhIL-
1β, rhRANTES, rhTGF-β1, rhTNF-α or rhVEGF. In other experiments, cells were incubated for 
24 h in flasks coated with LM-111, type I collagen, fibronectin, vitronectin or LM-511/LM-521. 
Messenger RNA responses were investigated by qRT-PCR as described recently [32]. In 
addition, SF were stimulated with three different LPS serotypes to detect LPS-induced artefacts. 
In this study, the viability of cells was above 90% in all experiments as determined by trypan-
blue dye exclusion.  
 
Cell attachment analysis  
Long-term binding of SF to different components of the extracellular matrix (ECM) was 
investigated by a multiple substrate array (MSA®) [35]. To directly visualize the effects of TGF-
β1 on the initial attachment of SF to LM-111, cells were pre-activated in complete medium for 24 
h with TGF-β1. Untreated SF served as controls [36]. Aliquots of LM-111 solutions in PBS were 
immobilized on plastic dishes by air-drying at room temperature. The LM-111-coated surfaces 
were sealed with blocking solution (1% BSA/PBS). Then 2x105 cells were allowed to attach to 
LM-111 for 15 min in serum-free medium. Non-adherent cells were removed and attachment of 
SF to LM-111 was evaluated by microscopy. To investigate the role of integrins for attachment 
of SF to LM-111, cells were pre-incubated with different anti-integrin antibodies. Then the 
attachment assays were performed as described above. 
 
Cell signaling  
We investigated the contributions of the p38MAPK, ERK1/2, and SMAD2 pathways to the 
expression of IL-16 utilizing the following reagents: p38MAPK was inhibited by SB203580, 
MEK1/2 – ERK1/2 kinases by PD98059 [37], and SMAD2 by A-83-01 [38]. The cells were 
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grown overnight on LM-111, pre-incubated for 30 min in the presence or absence of the specific 
inhibitors, and then activated with TGF-β1. The effects on the regulation of IL-16 were 
investigated by qRT-PCR after 24 h of incubation and compared to controls. 
 
Detection of cytokines 
Intracellular IL-16 protein was detected by immunoblot utilizing an anti-IL16 antibody 
followed by anti-Ig-peroxidase, and signals were developed by a chemiluminescence protocol. 
Production of IL-16 was detected in supernatants of SF seeded in normal or LM-111-coated 24-
well plates in complete medium. Then the medium was removed and the cells were starved 
overnight in 0.1% FCS / DMEM medium and incubated for 24 h in the presence of rhIL-1β or 
rhTGF-β1. Supernatants were harvested, pre-cleared by centrifugation (12,000 xg, 4°C, 5 min) 
and analyzed by ELISA. Supernatants from mock-treated SF and cell culture medium served as 
controls [39]. 
 
Cell migration assay  
Functional tests of IL-16 activity were performed with a cell migration assay [5]. PBMC 
were freshly isolated and incubated in a Boyden chamber. Supernatants from TGF-β1− and/or 
LM-111-activated RA-SF or OA-SF were added to the chamber. Complete medium or 
supernatants from mock-treated cells served as controls. Migration of PBMC across the 
membrane was quantified to investigate the activity of IL-16. The addition of anti-IL-16 mAB 
(10 μg/mL, clone 17.1) was used to show IL-16 specificity in this assay. 
 
Flow cytometry 
The expression of integrins on SF was investigated by flow cytometry. Briefly, the cells 
were detached with Accutase® and resuspended in PFEA buffer. Where applicable, SF were pre-
incubated in Gamunex® to eliminate unspecific binding of antibodies. The SF were incubated 
with the primary antibody for 20 min at 4°C, washed, and incubated with the secondary antibody 
for 20 min at 4°C. Then cells were re-suspended in PFEA buffer and analyzed by flow cytometry. 
Data were evaluated using the software program FlowJo®. 
 
Immunoblot analysis  
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Signal transduction pathways were investigated by immunoblotting [39]. After activation 
with TGF-β1 for 10 min to 22 h, the cells were subjected to SDS-PAGE and immunoblot analysis 
as described [38]. Proteins were transferred to nitrocellulose membranes, blocked and probed 
overnight at 4°C with anti-pan-p38MAPK, anti-phospho-p38MAPK (Thr180/Tyr182), anti-
phospho-ERK1/2 (Thr202/Tyr204), anti-phospho-SMAD2 (Ser465/467), anti phospho-NFκB 
(Ser536), or anti-pan-NFκB. Binding of the primary antibodies was detected using peroxidase-
labeled goat anti-rabbit-IgG antiserum, visualized by enhanced chemiluminescence and recorded 
with a CCD camera system. Expression of the integrin α7 molecule was also detected by 
immunoblot utilizing mAB clone IGTA7. 
 
Statistics  
Statistical evaluation was carried out using a two-sided T-test to investigate differences 
between individual sets of data. Probability values (p) equal to or less than 0.05 (*), 0.01 (**) or 
0.001 (***) were considered to be statistically significant and marked in the figures accordingly. 
A detailed description of all techniques and reagents utilized is found in the supplementary files 
[to be] published online [if accepted for publication]. 
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RESULTS 
 
Transforming growth factor-β1 augments LM-111-induced IL-16 gene activity. 
Binding of SF to LM-111 induced a significant IL-16 mRNA response which was 
significantly higher in RA-SF than in OA-SF (Fig. 1). Binding of RA-SF or OA-SF to type I 
collagen, fibronectin and vitronectin had no influence on the regulation of IL-16 transcripts (see 
supplementary files Fig. S5A), but binding of SF to LM-111 did not differ significantly from 
binding to any of the proteins investigated (Fig. S5B). TGF-β1 induced significant IL-16 mRNA 
responses in RA-SF and OA-SF (Fig. S5C). The addition of TGF-β1 to OA-SF binding to LM-
111 induced a highly significant expression of IL-16 mRNA, but an even higher IL-16 response 
was seen in RA-SF (Fig. 1). The addition of RANTES to SF grown on LM-111 failed to augment 
the IL-16 response as induced by binding of SF to LM-111 alone. In RA-SF binding to LM-111, 
the TGF-β1-enhanced expression of IL-16 was significantly higher than the corresponding 
RANTES-activated expression (Fig. 1). 
 
Next we investigated the initial attachment of SF to LM-111 in more detail. In short-term 
attachment experiments SF activated by TGF-β1 adhered more strongly to LM-111 compared to 
controls (Fig. S6). The SF spontaneously express integrins which are known to be involved in the 
binding of cells to LM-111, including the α1-, α7-, and β1-integrin chains (Fig. S7). A weak 
expression of α2- and α9-integrin was observed, whereas the α6- and β4-integrins were not 
detected on SF. Expression of the collagen-binding α3-integrin was detected as well (Fig. S7). 
Activation of SF by TGF-β1 slightly enhanced the expression of β1-integrin, but not the 
expression of any of the integrin α–chains investigated (Fig. 2A). Attachment of SF to LM-111 
through β1-integrin was functionally blocked by mAB 4B4. In contrast, pre-incubation of SF 
with anti-α2- or anti-α9-integrins (mAB P1E6 or Y9A2, respectively) did not reduce binding of 
SF to LM-111. Blocking the collagen-binding α3-integrin also failed to reduce the binding of SF 
to LM-111 (Fig 2B), but reduced binding to collagen (not shown). Incubation of SF with anti- 
α6-integrin (Fig 2B) or anti-β4-integrin (not shown) served as control. 
 
To investigate the signaling pathways addressed in SF by TGF-β1 and LM-111, SF were 
incubated in LM-111-coated flasks and activated by the addition of TGF-β1 for different periods 
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of time. Weak phospho-p38MAPK signals peaked 30 min after activation of the cells (Fig. S8A). 
Phosphorylation of ERK was detected in SF prior to stimulation, but strong phospho-ERK signals 
were seen 10 min to 2 hours after activation (Fig. S8A). Phosphorylation of SMAD2 was not 
observed prior to activation of SF, but was seen 10 min after addition of TGF-β1 and remained 
detectable at low levels thereafter (Fig. S8A). The involvement of p38MAPK, ERK and SMAD2 
signaling in the regulation of IL-16 expression was confirmed by pharmacological blocking 
reagents (Fig. S8B). Note that NFκB was not involved in the LM-111- and TGF-β1-induced 
regulation of IL-16 (Fig. S8A). 
 
Detection of the IL-16 cytokine.  
Intracellular IL-16 protein was detected in extracts of RA-SF and OA-SF by immuno-
blotting. The IL-16 protein was detected in comparable amounts in both RA-SF and OA-SF. 
Activation of RA-SF or OA-SF by binding to LM-111 in the presence of TGF-β1 failed to 
augment the cytoplasmic expression of the IL-16 protein (Fig. 3A).  
 
Spontaneous release of the IL-16 cytokine was not detected in supernatants of RA-SF, OA-
SF (Fig. 3B), or orbital fibroblasts (not shown). Binding of RA-SF or OA-SF to LM-111 did not 
induce the release of IL-16 (not shown). The addition of TGF-β1 to serum-starved RA-SF 
induced a significant IL-16 response. This response was significantly enhanced in RA-SF binding 
to LM-111 in the presence of TGF-β1 (Fig. 3B). The addition of TGF-β1 to serum-starved OA-
SF failed to induce the production of IL-16, even upon attachment to LM-111 (Fig. 3B). IL-1β 
induced production of IL-16 in RA-SF, OA-SF, and orbital fibroblasts served as positive controls 
(Table S2). It is worth noting that neither binding to LM-111 nor activation by TGF-β1 induced a 
substantial IL-1β production in SF (Fig. S9). Furthermore, stimulation of SF with LPS failed to 
induce an IL-16 response (Fig. S10). 
 
The biological activity of SF-produced IL-16 was investigated by a cell migration assay 
with PBMC. In supernatants from unstimulated, serum-starved RA-SF or OA-SF, the addition of 
anti-IL16 mAB failed to reduce PBMC counts, indicating that the cells spontaneously secreted 
very little IL-16, but may produce other chemoattractants (Fig. 4). Attachment of RA-SF to LM-
111 and the addition of TGF-β1 triggered significant secretion of chemoattractant factors after 
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serum starvation of these cells. This effect was reduced by the addition of anti IL-16 mAB, 
confirming that co-stimulation of RA-SF by TGF-β1 and LM-111 induced the production of 
biologically active IL-16. In contrast, in OA-SF supernatants neither chemoattractant activity nor 
IL-16 was detected (Fig. 4).  
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DISCUSSION 
 
Here we describe a novel IL-16 regulatory pathway which proceeds independently of the 
two key cytokines in RA, TNF-α  and IL-1β [40]. Instead, it requires TGF-β1 or binding of the 
cells to LM-111 in the presence of TGF-β1. The TGF-β1 not only elevates IL-16 transcript levels 
in SF, but enhances the expression of the LM-111-binding β1-integrin. This in turn facilitates the 
binding of SF to LM-111 and may thus enhance integrin-mediated signaling. In contrast to the 
IL-1β- or IGF-1-induced regulation of IL-16 [5, 29], the TGF-β− and LM-111-dependent 
production of the IL-16 protein in supernatants was observed only in RA-SF. In supernatants of 
LM-111 plus TGF-β1-activated OA-SF, production of IL-16 was detected neither by ELISA nor 
by a specific assay for IL-16 activity. Intracellular IL-16 was detected in both RA-SF and OA-SF, 
but activation of the cells by LM-111 and TGF-β1 did not significantly increase the amounts of 
mature intracellular IL-16 in SF. This indicates that regulation of IL-16 responses in SF occur 
only in part on the mRNA level: incubation of SF on LM-111 induced moderate, but highly 
significant IL-16 mRNA responses compared to the incubation of SF on other ECM proteins. 
This mRNA response was significantly stronger in RA-SF than in OA-SF and may enable RA-SF 
to refill their IL-16 protein reservoir more rapidly than OA-SF. In RA-SF, the LM-111 plus TGF-
ß1 signals were sufficient for the production of significant amounts of biologically active IL-16. 
In contrast, IL-16 was not detected in supernatants of OA-SF. In OA-SF the release of IL-16 
requires additional stimuli such as IL-1β. In a comparable fashion, intracellular IL-16 was 
detected in CD4+ and in CD8+ T lymphocytes [24], but the release of IL-16 from CD4+ T 
lymphocytes required specific activation [23]. IL-1β represents one such stimulus for fibroblasts, 
possibly affecting the post-translational processing of the 68 kDa IL-16 precursor to generate the 
14 kDa IL-16 monomer and cause its export into the pericellular lumen [27, 30]. 
 
In RA-SF, expression of IL-16 could be induced by immunoglobulin (Ig) preparations 
isolated from the sera of RA patients, but the same Ig preparations failed to induce the expression 
of IL-16 in OA-SF [31]. Thus, a disease-associated activation of cells seems to render RA-SF 
more sensitive to Ig- or LM-111-induced signals. The strong expression of laminins in the RA 
synovial tissue [21] seems to facilitate the TGF-β1-induced expression of IL-16. Elevated 
expression of LM-111 was also described in endometriotic lesions, and anti-LM-111 
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autoantibodies were found in these patients [41]. Moreover, elevated levels of IL-16 were 
detected in the peritoneal fluid of women with endometriosis [42]. Our data provide an 
explanation for these findings: binding of cells to LM-111 facilitates the expression of IL-16. 
Furthermore, TGF-β1 enhanced the initial attachment of SF to LM-111 in a dose- and time-
dependent manner. It enhanced the expression of the integrin β1-chain slightly and may modulate 
integrin activation [43]. The β1 integrin is involved in this enhanced binding of SF to LM-111, 
since pre-incubation of SF with mAB 4B4 blocked the binding of SF to LM-111. The 
involvement of integrin α-chains in this context remains to be investigated, as the blocking 
experiments utilizing antibodies to the LM-111-binding α2-, α6-, and α9-integrins were 
inconclusive, and antibodies to the α1− and  α7-integrins were not available for functional 
blocking experiments. 
 
The enhanced attachment of TGF-β1-activated SF seems to contribute to the enhanced co-
signaling pathway. We recently showed that attachment of SF to LM-111 extended or enhanced 
the TGF-ß-induced phosphorylation of ERK1/2 compared to controls. Furthermore, LM-111 plus 
TGF-β co-signaling involved phosphorylation of p38MAPK and SAPK [32]. Integrin signaling is 
associated with the MEK-ERK pathway. Therefore attachment of SF to LM-111 may contribute 
to the activation of ERK. But this was not investigated in depth. Activation of SF by TGF-β1 
may also change the extracellular conformation of the β1-integrin. Reorientation of their 
ectodomain enables integrins to bind the ligands with higher affinity [43]. This form of TGF-β1-
activated inside-out signaling could modulate the attachment of SF to LM-111 and, as a 
consequence, LM-111-dependent cell signaling as well. In addition, SF may utilize other 
receptors for attachment or binding to LM-111, which may be induced by TGF-β1 [44- 46]. The 
elevated expression of integrins reported on RA-SF compared to OA-SF may make these cells 
more sensitive than OA-SF to ECM signaling [22], but it does not necessarily cause a stronger 
binding of RA-SF to ECM proteins, at least as investigated by MSA® in vitro.  
 
In summary we show that RA-SF differ significantly from OA-SF in their sensitivity to 
LM-111-induced expression of IL-16 mRNA and that TGF-β1 activates the expression of IL-16 
mRNA in OA-SF, but does so to an even greater extent in RA-SF. Attachment of SF to LM-111 
by β1 integrin enhances this effect significantly. Production of the IL-16 cytokine is observed in 
 12
TGF-β1-activated RA-SF, but not in TGF-β1-activated OA-SF, and this effect is significantly 
enhanced by attachment of RA-SF to LM-111. In this study we describe a novel, NFκB-
independent pathway of IL-16 expression induction that involves phosphorylation of p38MAPK, 
ERK1/2 and SMAD2. Although this mode of activation does not seem to involve huge amounts 
of IL-16 per cell, it may maintain low-level inflammation in RA in the absence of TNF-α or IL-
1β. 
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FIGURE LEGENDS. 
Figure 1 
Induction of IL-16 mRNA by attachment to LM-111 in presence of TGF-ß1 
SF were incubated for 24 h in complete medium in normal cell culture flasks (control) or in flasks 
coated with LM-111 without or after the addition of 50 ng/mL RANTES (LM + RANTES) or 10 
ng/mL TGF-β1 (LM + TGF-β). Incubation of SF on LM-111 in the absence of additional factors 
induced a moderate, but statistically significant increase in the IL-16 signal (OA-SF mean 1.67-
fold ± 0.32, p<0.002, n=9) / RA-SF mean 2.04-fold, ± 0.43, p<0.001, n=7) in comparison to 
controls. This IL-16 mRNA response was significantly higher in RA-SF than in OA-SF (bracket, 
p<0.035). The addition of RANTES to OA-SF or RA-SF grown on LM-111 failed to further 
augment IL-16 qRT-PCR signals in comparison to cells on LM-111 only. Addition of TGF-β1 to 
SF binding to LM-111 raised IL-16 qRT-PCR signals significantly in comparison to controls 
(OA-SF: mean 2.49 fold ± 0.6, p<0.001, n=9 / RA-SF: mean 3.72 ± 0.97, p<0.001, n=8). The 
LM-111 plus TGF-β−activated IL-16 transcript levels were significantly higher in both OA-SF 
and RA-SF in comparison to the cells on LM-111 without additional cytokines (solid lines, 
p<0.005 each). In LM-111 plus TGF-β RA-SF, IL-16 transcript levels were significantly higher 
than in LM-111 plus RANTES-activated cells (dotted line, p<0.002). Mock-treated SF served as 
controls (=100%). 
 
Figure 2 
(A) Effect of TGF-ß1 on expression of integrins on SF  
Activation of SF by TGF-β1 (10 ng/mL, 24h) enhanced the expression of the LM-111-
binding β1-integrin on SF (+) compared to non-activated controls (-). In contrast, TGF-β1 did 
not alter the signal intensity observed for expression of any of the LM-111-binding integrin 
α-chains (i.e., α1, α2, α6, α9) investigated. Staining the collagen-binding α3-integrin served 
as control. 
(B) Blocking attachment of SF to LM-111 by anti-integrin monoclonal antibodies 
Initial attachment of SF to LM-111 could be inhibited by anti-β1 integrin antibody. SF were 
preincubated for 15 min with mAb to α2-, α3-, α6-, α9-, and β1-integrin chains and seeded 
onto LM-111. Pre-incubation with anti-β1 integrin antibody blocked attachment of SF, 
 20
whereas the other antibodies showed no effects on binding of cells to LM-111. SF seeded to 
LM-111 w/o pre-incubation with an anti-integrin antibody served as control (c). 
 
Figure 3 
(A) Detection of the IL-16 protein in SF 
RA-SF and OA-SF were incubated overnight in LM-111-coated flasks in the presence of 30 
ng/mL TGF-β1 (+). For comparison, cells were also left untreated (-). Cells were harvested, 
washed and cytoplasmic proteins were extracted. 100 μg/lane of cellular extract were separated 
by SDS-PAGE, blotted, and incubated with goat anti-human IL-16. Binding of anti-IL-16 
antibodies was detected by HRP-labeled rabbit anti-goat Ig and signals were visualized by 
chemiluminescence. Intracellular IL-16 was detected in RA-SF and OA-SF in comparable 
amounts. TGF-β1 did not regulate intracellular IL-16 protein amounts in SF. 
(B) Detection of the IL-16 cytokine in SF supernatants 
RA-SF (n=4) and OA-SF (n= 8) were grown overnight on normal plates in the presence of TGF-
β1 (TGF−β) or on LM-111-coated plates in the presence of TGF-β1 (LM-111+TGF-β). Cells on 
normal plates without TGF-β1 and cell culture medium served as controls. Supernatants were 
harvested and IL-16 was detected by ELISA. In controls, IL-16 was not detected (sensitivity ≈ 17 
pg/mL, dotted line). The addition of TGF-β1 induced a significant IL-16 response in RA-SF 
(38.3±10 pg/mL, p<0.001) that was almost doubled by binding of the RA-SF to LM-111 
(62.5±14.75, p< 0.01). The TGF-β1-induced IL-16 response was significantly higher in RA-SF 
binding to LM-111 than in RA-SF in normal flasks (p<0.026). In supernatants of OA-SF, IL-16 
production remained below the detection limit. 
 
Figure 4 
Synovial fibroblasts produce IL-16-specific chemotactic activity 
The OA-SF (n=2, gray bars) or RA-SF (n=5, black bars) were grown to confluence in LM-111-
coated 24-well plates, and incubated for 24 h in 0.1% FCS starvation medium in the presence of 
10 ng/mL TGF-β1. The supernatants were investigated for chemotactic activity in a Boyden 
chamber using PBMC as target cells. Stimulation of serum-starved RA-SF by LM-111 in the 
presence of TGF-β1  significantly elevated chemotactic activity (134±8.6 a.u., p≤0.05), which 
was reduced by the addition of anti IL-16 mAB (116±5.5 a.u.). In supernatants of OA-SF, IL-16 
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and its chemotactic activity were not observed. Data represent the mean values and standard 
deviations of the differences between the total PBMC counts and the residual cell counts after the 
addition of anti-IL-16 antibodies (10 μg/mL, mAB clone 17.1) in arbitrary units (a.u.). 
Supernatants from mock-treated cells in the presence or absence of anti-IL-16 antibodies served 
as controls (= 100%). 
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SUPPLEMENTARY FILES FOR ONLINE PUBLICATION 
 
Detailed Materials and Methods: 
 
Cell culture.  
Synovial tissue samples were obtained after written consent from 17 RA and 24 OA 
patients diagnosed according to the revised ACR criteria [33] (Table S1). SF were isolated by 
mincing the tissue and then performing enzymatic disintegration as described [32, 34]. The cells 
were expanded in DMEM medium enriched with ITS (insulin-transferrin-selenium mix, Life 
Technologies, Karlsruhe, FRG), 10% FCS (Biochrome, Berlin, FRG) and antibiotics (Sigma, 
Taufkirchen, FRG, = complete medium). Orbital fibroblasts were obtained from surgical waste, 
prepared and expanded as described [5]. This study was approved by the local ethics committee.  
 
Table S1 
Diagnosis # of patients gender mean age mean CRP mean BSR DMARD steroids NSAR 
RA 17 m 7 / w10 62 0.79 29.1 14 / 17 11 / 17 5 / 17 
OA 24 m 11 / w13 66.8 0.41 13.8 0 / 24 2 / 24 12 / 24 
 
Clinical data of patients included in the study 
 
 
Activation of SF by cytokines or by attachment of cells 
For mRNA induction studies, SF were incubated in 10% FCS/DMEM medium (= complete 
medium) in the presence of 10 ng/mL rhIL-1β, 50 – 500 ng/mL rhRANTES, 0.1 to 30 ng/mL 
rhTGF-β1, 10 ng/mL rhTNF-α or 6 ng/mL rhVEGF (all from Roche, Mannheim, FRG or 
Calbiochem, Schwalbach, FRG). Cells in complete medium without the addition of cytokines 
served as controls. In other experiments, cells were incubated for 24 h in flasks coated with LM-
111 (EHS-laminin, 10 mg/mL, BD Bioscience, Heidelberg, FRG). Flasks coated with type I 
collagen, fibronectin, vitronectin (all from BD Biosciences) or human placenta laminin (=LM-
511/LM-521, 10 μg/mL, Chemicon, Schwalbach, FRG) served as controls. The time course of 
IL-16 mRNA induction was established by activating SF with 10 ng/mL TGF-β1 for 1 h to 24 h. 
Differences in gene expression were investigated by quantitative RT-PCR (qRT-PCR) in 
comparison to mock-treated cells. For additional controls SF were stimulated with two different 
LPS serotypes (100 ng/mL 026:B6, 100 ng/mL 0127:B8, Sigma) for 24 h to detect LPS-induced 
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effects. In this study, the viability of cells was above 90% in all experiments as determined by 
trypan-blue dye exclusion.  
 
Analysis of initial attachment and long-term binding of SF to matrix proteins.  
The binding of SF from six RA and six OA synovial specimen to different components of 
the extracellular matrix was investigated by a novel multiple substrate array (MSA®) technique 
[35]. Briefly, 12 extracellular matrix proteins (3 nL/microspot at a concentration of 0.05 – 
0.4mg/mL) were microspotted onto a nitrocellulose-coated glass slide and air-dried. The binding 
of cells to the following proteins was investigated: collagen type I, II, III (Sigma), IV (BD 
Biosciences), V (Sigma) and VI (BD Biosciences), cellular fibronectin (Chemicon), heparan 
sulfate proteoglycan, LM-111 (both Sigma), LM-511, tenascin-C (both Chemicon), and 
vitronectin (Sigma). Bovine serum albumin (Roth, Karlsruhe, FRG) and poly-L-lysine (Sigma) 
microspots served as negative and positive controls, respectively. The arrays were blocked by 
addition of StabilGuard (SurModics, Eden Prairie, MN) for 1 h at ambient temperature. The array 
slide was washed twice with PBS. Then, 2x104 SF were added to each array and the slide was 
incubated in DMEM supplemented with 1% FCS for 2 h in a pre-programmed shaking device 
(Variomag Teleshake, H+P Labortechnik AG, Oberschleißheim, FRG) and incubated for another 
2 h without shaking at 37°C. Non-adherent cells were gently washed off. Remaining SF were 
fixed onto the microspot by the addition of acidic methanol solution (50% methanol, 10% acetic 
acid, 0.05% w/v Coomassie™ Brillant Blue) and stained with 4',6-diamidino-2-phenylindole 
(DAPI, 0.5 µg/mL in PBS). The slides were mounted in 0.2 M Tris-HCl (pH 8.5), 25% (w/v) 
glycerol and 10% (w/v) Mowiol (Calbiochem) and cell numbers per microspot were determined 
by semi-automated microscopic image acquisition and analysis (Leica Qwin, Wetzlar, FRG). 
 
To directly visualize the effects of TGF-β1 on the initial attachment of SF to LM-111, the cells 
were pre-activated for 24 h with 10 ng/ml of rhTGF-β1 (Roche). Untreated SF served as controls.  
Aliquots (2 µL) of LM-111 solutions in PBS (1 µg/µl – 0.005 µg/µl) were immobilized onto 
plastic dishes (Greiner Bio-One, Frickenhausen, FRG) by air-drying at room temperature [36]. 
Non-specific binding of SF to the plastic dishes was prevented by pre-incubation with 1% BSA in 
PBS. 2x105 cells were allowed to attach for 15 min in serum-free medium (supplemented with 1 
mM CaCl2, 1 mM MgCl2, 25 µM MnCl2). Prior to cell spreading on the LM-111-coated spots, 
non-adherent cells were removed by gently rinsing the dishes with pre-warmed PBS. Specific cell 
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attachment was evaluated under a microscope (Zeiss Axiovert, Göttingen, FRG), and 
photographs of representative fields were taken. To inhibit attachment of cells to immobilized 
LM-111, SF were pre-incubated with different anti-integrin antibodies (diluted 1:50) for 30 min 
under constant agitation. After this pre-incubation period, the adhesion assays were performed in 
the presence of the respective antibodies as described above. 
 
Transcript analysis.  
The RNA was extracted from 106 SF using a spin column technique (RNeasy, Qiagen, 
Hilden, FRG). To generate cDNA, 1 μg of total RNA was reverse transcribed using oligo-(dT) 
primers and AMV-reverse transcriptase (Clontech, Heidelberg, FRG). A qRT-PCR system (qRT-
PCR, LightCycler®, Roche) and commercially available primer pairs (SearchLC, Heidelberg, 
FRG) were used to measure steady state mRNA levels of cytokine and integrin transcripts. The 
amplification of cDNA was performed in 35 cycles. Following 1 initial cycle (95°C 10 sec, 68°C 
10 sec, 72°C 16 sec, temperature transition rate 20°Csec-1) the annealing temperature was 
dropped to 58°C with a step size of 0.5°C. PCR amplification was evaluated by the “fit-points” 
method (LightCycler Operator Manual, Roche); the data show the mean mRNA induction index 
of an individual gene in the experimental sample relative to the mRNA in mock-treated controls 
and normalized to the housekeeping enzyme GAPDH. Known amounts of a recombinant 
standard DNA were used to calibrate each run. The quality of amplification was investigated by 
melting point analysis (95°C, 58°C 10s, 95°C). The PCR products were then separated by 
electrophoresis on 1.5% agarose gels and visualized by UV-activated ethidium-bromide 
fluorescence to confirm the expected size. 
 
Cell signaling.  
We investigated the contributions of the p38MAPK, ERK1/2 and SMAD2 pathways to the 
expression of IL-16 using the following reagents: p38MAP kinase was inhibited by the addition 
of SB203580 (20 μM, Calbiochem) and MEK1/2 and ERK1/2 kinases were inhibited by adding 
PD98059 (20 μM, Calbiochem, [37]) to the cells. Signaling via SMAD2 was blocked by the 
addition of an ALK-5 specific inhibitor, A-83-01 (100 nM, TGF-βR-I serine/threonine kinase 
blocker, Calbiochem, [38]). The cells were grown on LM-111 overnight. Specific inhibitors were 
added to the cells 30 min prior to addition of TGF-β1. SF without inhibitors served as controls. 
Then 10 ng/mL TGF-β1 were added and the cells were incubated for an additional 24 h. The 
 25
effects of the inhibitors on the regulation of IL-16 were investigated by qRT-PCR in TGF-β1-
activated SF with or without inhibitors. Untreated cells served as mock controls. 
 
Detection of cytokines in SF supernatants.  
IL-16 was detected in cell supernatants by seeding SF from four RA patients, eight OA 
patients, or orbital fibroblasts from one donor in normal or LM-111-coated 24-well plates in 
DMEM complete medium at a starting density of 5x104 cells/well and culturing them to 
confluency. Then the medium was removed and the cells were serum starved overnight in 0.1% 
FCS / DMEM medium and incubated for 24 h in the presence of 10 ng/mL IL-1β or 10 ng/mL 
TGF-β1 (from Calbiochem or Roche) or without cytokines. Mock-treated cells served as 
controls. Supernatants were harvested and pre-cleared by centrifugation (12,000 xg, 4°C, 5 min) 
and aliquots of 100 μL were subjected to an ELISA (λscan, Bio-Tek Instruments, Winooski, 
VM) as described by the supplier (R&D Systems, Wiesbaden, FRG). Known concentrations of 
rhIL-16 served as standards, cell culture medium as negative control. Production of IL-1β, TGF-
β1 or TNF-α was detected in SF supernatants using commercially available ELISA kits (GE 
HealthCare / Amersham Bioscience, Freiburg, FRG). 
 
Cell migration assay.  
Functional tests of IL-16 activity were performed with a cell migration assay using 
modified Boyden chambers as described [5]. PBMC were freshly isolated and incubated in the 
chamber. We then added medium alone or supernatants from RA-SF or OA-SF which had been 
stimulated by binding to LM-111 in the presence of 10 ng/mL TGF-β1. Supernatants from mock-
treated cells served as controls. Migration of PBMC across the membrane was quantified to 
investigate the activity of IL-16. The addition of anti-IL-16 mAB (10 μg/mL, clone 17.1) was 
used to show IL-16 specificity in this assay [5]. The data given represent the mean values of the 
differences between total and residual chemotactic activity (PBMC counts in arbitrary units, a.u.) 
after the addition of anti-IL-16 mAB. 
 
Flow cytometry. 
The expression of integrins α1 (FITC-labelled mouse mAB clone TS2/7, Abcam, 
Cambridge, UK), α2 (FITC-labeled mouse mAB clone 12F1-H6, BD Pharmingen), α3 (mouse 
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mAB, clone P1B5, Chemicon), α6 (PE conjugated mouse mAB, clone 450-30A, Abcam), α9 
(mouse mAB clone Y9A2, Abcam), β1 (mouse mAB, clone 4B4, Beckmann Coulter, Krefeld, 
FRG) and β4 (rat IgG, clone 439-9B, BD Bioscience) was investigated by flow cytometry. 
Briefly, the cells were detached enzymatically (Accutase®, PAA, Pasching, Austria) and 
resuspended in PFEA buffer (PBS with 2% FCS, 2mM EDTA, 0.01% sodium azide). Where 
applicable, unspecific binding of antibodies was blocked by preincubation of SF with 
immunglobulins (Gamunex®, Bayer, Leverkusen, FRG). After incubation with the primary 
antibody for 20 min at 4°C, the cells were washed. Then – where required – SF were incubated 
with the secondary antibody (PE-conjugated goat anti-mouse IgG, Jackson Immunoresearch, 
Newmarket, UK, or PE-conjugated donkey anti-rat IgG, Dianova, Hamburg, FRG, respectively) 
for 20 min at 4°C. The cells were washed with PBS, resuspended in PFEA buffer and analyzed 
by flow cytometry (BD LSR II, SanDiego, CA). Data were evaluated using the software program 
FlowJo (http://www.treestar.com/flowjo/). To detect changes in the expression of integrins upon 
stimulation of the cells by TGF-β1, the cells were activated by adding 10 ng/mL TGF-β1 
overnight, followed by flow cytometry as described above.  
 
Immunoblot analysis.  
To study the cytoplasmic pathways involved in TGF-β1− and LM-111-mediated signal 
transduction, we investigated the phosphorylation of signaling proteins. 1x106 SF were incubated 
overnight in LM-111-coated flasks. Then 10 ng/mL TGF-β1 were added for activation for 
different lengths of time (10 min to 22 h). Cells were harvested, lysed and subjected to SDS-
PAGE and immunoblot analysis as described [38]. Briefly, the cells were washed with cold PBS, 
harvested by mechanical detachment, collected by centrifugation and lysed in 100 μL buffer 
containing 150 mM NaCl, 50 mM Tris/HCl pH 8, 1% NP-40 and a cocktail of proteinase 
inhibitors (Roche). The extracts were stored overnight at –70°C. After the samples were thawed, 
insoluble debris was removed from the extracts by centrifugation (20,000 x g, 4°C, 30 min). The 
protein concentration was measured with a colorimetric assay according to the manufacturer’s 
instructions (Bio-Rad, Munich, FRG). An aliquot of 100 μg total cellular protein was mixed with 
Laemmli sample buffer, denatured at 95°C and then separated by electrophoresis in a 10% SDS-
PAGE. Proteins were transferred onto nitrocellulose membranes, blocked and probed overnight at 
4°C with anti-pan-p38MAPK, anti-phospho-p38MAPK (Thr180/Tyr182), anti-phospho-ERK1/2 
(Thr202/Tyr204), anti-phospho-SMAD2 (Ser465/467), anti phospho-NFκB (Ser563), or anti-
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pan-NFκB (all 1:1000, Cell Signaling Technology, Beverly, MA). After thorough rinsing of the 
membrane, binding of the primary antibodies was detected using peroxidase-labeled goat anti-
rabbit-IgG antiserum (1:1000, Dianova). The binding of antibodies was visualized by enhanced 
chemiluminescence (ECL, GE Healthcare) and recorded by a luminescence-sensitive CCD 
camera system (Diana, Raytest Inc., Straubenhardt, FRG).  
 
To detect intracellular IL-16, RA-SF (n=2 patients) and OA-SF (n=2 patients) were 
expanded, activated overnight by LM-111 and 30 ng/ml of TGF-β1, separated by SDS-page, and 
prepared for immunoblot as described above. IL-16 was detected by incubation of the blot with 
goat anti-human IL-16 (1:100; R&D Systems). Binding of anti-IL-16 serum was detected by 
HRP-labeled rabbit anti-goat Ig (1:500, Dianova). Human recombinant IL-16 (20 ng/lane; R&D 
Systems) served as control in each blot. Furthermore, since no mAB suitable for detecting the 
integrin α7 molecule by flow cytometry is available, we confirmed the expression of α7 integrin 
on SF by immunoblotting (mouse mAB clone IGTA7, Abcam, 1:1000) as described above. The 
Caco and Jurkat cell lines served as positive and negative controls, respectively. 
 
Statistics. Statistical evaluation of the experimental data was carried out using a two-sided 
T-test to investigate differences between individual sets of data. Probability values (p) equal to or 
less than 0.05 (*), 0.01 (**) or 0.001 (***) were considered to be statistically significant and 
marked in the figures accordingly. The data show the mean values ± standard deviations of the 
individual experiments. 
 
 
Additional Results: 
 
Induction of IL-16 transcripts by extracellular matrix proteins and cytokines.  
Incubation of OA-SF or RA-SF in flasks coated with collagen type I, fibronectin, or 
vitronectin did not lead to stronger IL-16 qRT-PCR signals than incubation in uncoated flasks (= 
control, Fig. S5A). On LM-111, RA-SF showed a higher induction of IL-16 mRNA (2.04 fold) 
and OA-SF yielded a weaker induction of IL-16 mRNA (1.67 fold) in comparison to the 
respective controls. This induction of IL-16 transcripts by LM-111 was significantly higher in 
RA-SF than in OA-SF (p<0.035, Fig S5A). Among the RA-SF, 2/9 samples failed to respond to 
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LM-111 (mean 1.15 fold ± 0.17), whereas among the OA-SF 5/14 samples failed to show an IL-
16 response (mean 1.03 fold ± 0.13). Incubation of SF on LM-511/521 failed to induce an IL-16 
response (not shown), showing that this effect was specific for LM-111. 
 
Binding of RA-SF to extracellular matrix proteins in comparison to OA-SF.  
As the activation of expression of IL-16 mRNA by LM-111 was possibly associated with 
differences in strength of binding of RA-SF and OA-SF to LM-111 in comparison to the other 
ECM proteins, we investigated the binding of six RA-SF and OA-SF samples utilizing a novel 
MSA® technique [35]. The SF bind well to poly-L-lysine and with comparably high affinity to 
collagen type I, fibronectin, vitronectin, and LM-111 (Fig. S5B). This MSA® analysis was 
repeated twice; no significant difference was found between RA-SF and OA-SF with respect to 
binding to these matrix proteins or to any of the other eight proteins investigated (not shown). We 
found no evidence that RA-SF differed significantly from OA-SF with respect to long-term 
binding to ECM proteins in vitro, at least after incubation of the SF on the ECM compounds for 
two to four hours and without activation by TGF-β1, respectively. 
 
Regulation of IL-16 transcripts by cytokines 
Next we tested cytokines, which have never before been investigated with respect to the 
regulation of IL-16 mRNA responses in SF. Neither RANTES nor VEGF elevated IL-16 mRNA 
in SF, but TGF-β1 augmented the expression of IL-16 significantly (Fig. S5C). RA-SF showed a 
higher induction of IL-16 mRNA than OA-SF, but this difference did not reach statistical 
significance (p≤0.09). Furthermore, the addition of TNF-α reduced IL-16 mRNA both in OA-SF 
and in RA-SF (Fig. S5C). 
 
Effect of TGF-ß1 on the attachment of SF to LM-111. 
Initial attachment of TGF-β1-activated SF to LM-111 was investigated by a cell 
attachment assay [36]. Fifteen minutes after inoculation and prior to spreading of the cells, TGF-
β1-activated SF covered the LM-111-coated surfaces more densely than controls (Fig. S6A). 
However, this difference in SF binding on LM-111 spots vanished after longer incubation periods 
(t ≤ 30 min, not shown). The threshold amount of LM-111 that still bound SF was determined to 
be 0.005 μg per spot. Under these conditions, both mock-treated and TGF-β1-activated SF failed 
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to bind sufficiently to LM-111 (Fig. S6B). Spotting as little as 0.05 μg of LM-111 yielded 
binding of TGF-β1 activated SF, whereas no control cells bound specifically to 0.05 μg of LM-
111. About 0.25 μg/spot of LM-111 or more were required for an efficient attachment of mock-
treated SF (Fig. S6B). However, on the latter spots clearly more TGF-ß-activated SF were 
detected. 
 
To determine which receptors might be involved in the binding of SF to LM-111, we 
investigated the expression integrins on SF by flowcytometry (Fig. S7A). Expression of α6- and 
β4-integrins were not detectable on SF, α2- and α9-integrin were dim. Expression of α1-integrin 
was detected on SF, and α3-, and β1-integrins yielded bright staining (Fig. S7A). The expression 
of the integrin α7 molecule by SF was detected by immunoblotting (Fig. S7B).  
 
Transforming growth factor-β1 and LM-111 co-signaling activates the p38MAPK, ERK1/2 
and SMAD2 pathways. 
 To investigate the signaling pathways addressed in SF by TGF-β1 and LM-111, SF were 
incubated in LM-111-coated flasks and activated by the addition of TGF-β1 for different periods 
of time. Detection of total p38MAPK and NFκB served as loading controls. Weak phospho-
p38MAPK signals were noted which peaked 30 min after activation of the cells (Fig. S8A). 
Phosphorylation of ERK was detected in SF prior to stimulation, but strong phospho-ERK signals 
were seen 10 min to 2 hours after activation (Fig. S8A). In contrast, no phospho-SMAD2 signal 
was detected prior to the addition of TGF-β1. Phosphorylation of SMAD2 was observed 10 min 
after activation by TGF-β1 and remained detectable at low levels thereafter (Fig. S8A). 
Phosphorylation of NFκB was not detected, but total NFκB was observed in all extracts (Fig. 
S8A).  
To determine the roles of p38MAPK, ERK and SMAD2 signaling more precisely, SF were 
grown on LM-111 and activated with TGF-β1 in the presence or absence of SB203580, PD98059 
or A-83-01. This co-activation of SF by LM-111 and TGF-β1 induced a significant IL-16 mRNA 
response, which was significantly reduced by SB203580, PD98059 or the addition of A-83-01 
(Fig. S8B), thus confirming that p38MAPK, ERK and SMAD2 proteins play a role in the 
regulation of IL-16 expression. 
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Mode of TGF-β-activated IL-16 expression.  
As IL-1β induced secretion of the IL-16 cytokine in RA-SF, OA-SF and orbital fibroblasts 
[5, 29, 31] (and Table S2), we investigated whether the attachment of RA-SF or OA-SF to LM-
111 in the presence or absence of TGF-β1 would induce the production of IL-1β (Fig. S9). Low 
levels of IL-1β release were detected in supernatants of SF activated by TGF-β1 (10 ± 2.6 pg/mL, 
p<0.04) or by TGF-β1 together with LM-111 (10.9 ± 2.3 pg/mL, p< 0.007). Supernatants from 
SF attached to LM-111 (7.3 ± 1.5 pg/mL) or from cells in normal culture flasks (7.3 ± 1.6 pg/mL) 
contained even less IL-1β. The cell culture medium contained some IL-1β (4.1 ± 0.21 pg/mL, 
Fig. S9). Release of TNF-α was not observed in any of the samples tested (not shown). In time 
course experiments, the addition of 10 ng/mL of TGF-β1 elevated IL16 transcript amounts as 
early as two hours after induction (not shown). In addition, to induce IL-16 expression in SF, we 
activated the cells with 10 ng/mL IL-1β (Table S2). This supports the supposition that TGF-β-
modulated IL-16 regulation is not dependent on the expression of IL-1β or TNF-α. 
 
Induction of IL-16 transcripts is not induced by LPS 
As preparations of recombinant cytokines or proteins utilized to coat the flasks may contain 
trace amounts of LPS, we investigated if IL-16 transcripts might be activated by LPS. (Fig. S10). 
The addition of LPS to SF did not augment the amounts of IL-16 mRNA, but induced elevated 
steady state mRNA levels encoding IL-1β (132-fold), IL-6 (21-fold), IL-8 (108-fold), MMP-1 
(3.4-fold) and MMP-3 (11-fold, not shown). Note that, as seen upon activation of SF by TNF-α 
(Fig. 1B), the activation of cells by LPS1 instead reduced IL-16 transcript signals (Fig. S10). This 
indicated that induction of IL-16 by LM-111 and TGF-β1 was not associated with an LPS 
artefact, confirming recent results [49]. Furthermore, as LPS activates SF through toll-like 
receptors and signals through the NFκB pathway, this result corroborates our notion that NFκB is 
not required for the induction of IL-16 expression (Fig. S8A). 
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Table S2 
Cell       # Donors  IL-16 (pg/mL) 
RA-SF    4  108±23  
OA-SF    1  118± 23  
orbital fibroblasts  1  154±27 
controls   2  < 7 
 
Induction of IL-16 expression in SF by IL-1ß 
The SF were incubated in triplicate in 24-well plates and grown to confluency in 
complete medium. As soon as confluency was reached, the medium was removed 
and replaced by starvation / induction medium (0.1% FCS, enriched with 10 
ng/mL rhIL-1β). The cells were incubated for 24 h. Supernatants were harvested 
and the IL-16 expression was determined by ELISA. Serial dilutions of rhIL-16 of 
known concentrations served as controls. Data given represent the mean IL-16 
concentration ± standard deviation in pg/mL. 
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Supplemental Figure Legends: 
 
Figure S5 
 
Induction of IL-16 mRNA by cytokines or extracellular matrix compounds 
(A) Cells were incubated for 24 hours on protein-coated flasks as indicated. Growth of cells on 
LM-111 induced a moderate but statistically significant increase in IL-16 qRT-PCR signals 
in RA-SF (mean 2.04 fold, ± 0.43, p<0.001, n=7), but a weaker IL-16 response in OA-SF 
(mean 1.67 fold ± 0.32, p<0.002, n=9). The IL-16 induction index was significantly higher 
in RA-SF than in OA-SF (black line, p<0.035). Cells attached to type I collagen, 
fibronectin or vitronectin did not show IL-16 responses. Cells attached to uncoated flasks 
served as controls (= 100%). 
(B) Binding of OA-SF (n=2, gray bars) and RA-SF (n=2, black bars) to proteins was 
investigated using the multiple substrate array (MSA®) technique. Attachment to poly-L-
lysine (PLL, 100%) served as positive and BSA as negative (0%) controls, respectively. 
Binding of RA-SF did not differ significantly from that of OA-SF on any of the proteins 
investigated, including collagen type I, fibronectin, LM-111 and vitronectin. 
(C) Cells were incubated in uncoated flasks. The IL-16 encoding mRNA was quantified in SF 
after incubation with cytokines for 24 h. The addition of 50 ng/mL RANTES or 6 ng/mL 
VEGF had no regulatory effect, but 10 ng/mL TGF-β1 increased the numbers of IL-16 
transcripts significantly in both OA-SF (mean 1.86 fold ± 0.84, p< 0.01, n=7) and RA-SF 
(mean 2.56 fold ± 0.74, p<0.001, n=6) in comparison to untreated controls (= 100%). The 
addition of 10 ng/mL rhTNF-α reduced IL-16 mRNA to some extent in OA-SF (0.71 fold ± 
0.46, n=4) and significantly in RA-SF (0.25 fold ± 0.19, p< 0.001, n=5). 
 
Figure S6 
Effects of TGF-ß on the attachment of SF to LM-111 
(A) Initial attachment of SF was investigated by incubating SF directly on spots coated with LM-
111. SF were incubated overnight in complete medium in the presence or absence of 10 
ng/mL TGF-β1, harvested, and inoculated on spots coated with 1 μg of LM-111. Fifteen min 
after inoculation and prior to cell spreading, samples were rinsed with PBS to remove 
unbound SF. TGF-β1-activated cells attached more densely to LM-111 than controls. 
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Interestingly, both TGF-β1-activated SF and controls barely attached to the BSA-sealed 
surface (upper right part each).  
(B) Initial attachment of SF to LM-111 was investigated as a function of the LM-111 
concentration on the spot. SF were prepared as described above and incubated for 15 min on 
spots coated with serial dilutions of LM-111 as indicated. TGF-β1-activated SF attached well 
even to spots coated with as little as 0.05 μg of LM-111. In contrast, in controls far fewer 
cells attached to spots coated with 0.25 μg LM-111. The threshold for SF attachment to LM-
111 lies at 0.005 μg LM-111 per spot. 
 
Figure S7 
Spontaneous expression of LM-111-binding integrins in SF 
(A) Expression of integrins on SF was investigated by flow cytometry. SF were incubated 
with antibodies specific for the α1-, α2-, α3-, α6-, α9-, β1-, and β4-integrin chains. LM-
111-binding integrins [47] are marked in bold letters. Dashed profiles denote unstained 
cells, dotted lines second antibody only controls, and solid lines the cells stained with 
anti-integrin plus labeled detection antibodies. Expression of α1-, α3-, and β1-integrins 
was detected by flow cytometry, staining for α2- and α9-integrin was dim, α6- and β4-
integrins were not detected.  
(B) As the anti-α7-integrin mAB at hand is not suitable for flow cytometry, we detected 
expression of this LM-111-binding component [47] by immunoblot. In SF, a 100 kD 
integrin α7 protein was detected (lane 1). In Jurkat T-lymphoma cells a weak 130 kD 
component was observed (lane 2). In the epithelial adenocarcinoma cells Caco-2, both a 
prominent 100 kD integrin α7 protein and a weak 130 kD protein were observed (lane 3). 
The MW of proteins in shown in kDa (lane M). 
 
Figure S8 
Signal transduction pathways induced by LM-111 and TGF-β 
(A) The cells were incubated in LM-111-coated cell culture flasks overnight. Then 10 ng/mL 
of TGF-β1 were added and the signal transduction pathways were investigated using 
phospho-specific antisera to p38MAPK, ERK1/2, SMAD2 and NFκB. Total p38MAPK 
was detected in all samples. Phosphorylation of p38MAPK was observed 30 min after the 
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addition of LM-111 plus TGF-β1−stimulated SF. Phospho-ERK was observed in all 
samples. It was transiently enhanced after 10 min to 2 hours of activation by LM-111 and 
TGF-β. This co-signaling also induced phosphorylation of SMAD2 after 10 min of 
induction, and the phospho-SMAD2 signals remained detectable after 4 to 22 hours of 
incubation. Phosphorylation of NFκB was not observed, but total NFκB was detected in 
all extracts. (M = molecular weight marker, P = positive control extract) 
(B) The SF were stimulated by attachment to LM-111 and the addition of 10 ng/mL TGF-β1 
in the presence or absence of SB203580, PD98059 or A-83-01 for 24 h of incubation. 
Then IL-16 transcripts were enumerated by qRT-PCR. Activation of SF by LM-111 and 
TGF-β caused significant induction of IL-16 mRNA (mean 3.44-fold, ±1.6, p<0.008, 
n=6). Blocking p38MAPK activity by SB203580 reduced the IL-16 mRNA response 
significantly (6.6-fold, p<0.003, n=5); blocking the MEK – ERK pathway by PD98059 
or the Smad2 pathway by A-83-01 reduced the IL-16 response 3.2-fold (p<0.02, n=4) 
and twofold (n=4), respectively. Mock-treated SF served as controls (=100%). 
 
Figure S9 
Regulation of IL-1β expression in fibroblasts 
Synovial fibroblasts were activated overnight by binding to LM-111, by the addition of 10 ng/mL 
TGF-β1 or by binding to LM-111 in the presence of TGF-β1. Cell culture medium and 
supernatants from cells without stimulation served as controls. Production of IL-1β was measured 
by ELISA in triplicate samples (n= 7 SF, detection limit < 0.5 pg/mL), and data are presented as 
mean values (± standard deviations). Binding of SF to LM-111 yielded concentrations of 7.28 
pg/mL (± 1.47) of IL-1β, which did not differ from controls (7.28 pg/mL, ± 1.59), whereas TGF-
β1 or LM-111 plus TGF-β1 induced 10 pg/mL (± 2.6, p< 0.04) and 10.9 pg/mL (± 2.3, p< 0.007), 
respectively. This was significantly more IL-1β than in control cells. The cell culture medium 
contained some IL-1β (4.1 pg/mL ±0.21). 
 
Figure S10  
IL-16 mRNA expression is not activated by LPS in SF 
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SF (n=9) were incubated overnight in complete medium enriched with 100 ng/mL LPS1 
(026:B6) or 100 ng/mL LPS2 (0127:B8). Cells w/o LPS served as controls. SF were harvested 
and transcripts encoding IL-16 mRNA were enumerated by qRT-PCR. 












